Gradishar, WJ; Anderson, BO; Balassanian, R; Blair, SL; Burstein, HJ; Cyr, A; Elias, AD; Farrar, WB; Forero, A; Giordano, SH; Goetz, MP; Goldstein, LJ; Isakoff, SJ; Lyons, J; Marcom, PK; Mayer, IA; Mccormick, B; Moran, MS; O'Regan, RM; Patel, SA; Pierce, LJ; Reed, EC; Salerno, KE; Schwartzberg, LS; Sitapati, A; Smith, KL; Smith, ML; Soliman, H; Somlo, G; Telli, M; Ward, JH; Shead, DA; Kumar, R
These NCCN Guidelines Insights highlight the important updates/changes to the surgical axillary staging, radiation therapy, and systemic therapy recommendations for hormone receptor-positive disease in the 1.2017 version of the NCCN Guidelines for Breast Cancer. This report summarizes these updates and discusses the rationale behind them. Updates on new drug approvals, not available at press time, can be found in the most recent version of these guidelines at NCCN.org.